摘要
目的:探讨奎硫平治疗首发精神分裂症的疗效和安全性。方法:93例急性期精神分裂症患者随机分成2组,奎硫平组47例,氟哌啶醇组46例。分别治疗6周。采用阳性症状和阴性症状量表(PANSS)评定临床疗效,不良反应量表(TESS)评估药物不良反应。结果:奎硫平组治疗急性期精神分裂症显效率63.8%,有效率87.2%,无明显锥体外系反应。结论:奎硫平治疗精神分裂症疗效确切,不良反应少。
Objective：To explore the efficacy and safety of quetiapine and haloperidol in treatment of schizophrenia. Methods：93 cases of schizophrenia patients were randomly divided into two groups, quetiapine group （n = 47） and haloperidol group （n = 46）, All cases were treated for 6 weeks. Clinical efficacy and drug side effects were evaluated Using the PANSS Scale and TESS Scale. Results： Excellence and remission rate in quetiapine group was 63.8% and 87.2% respectively, and less Extrapyramidal reactions than another group. Conclusions ： Quetiapine with small - dose haloperidol effective in the treatment of acute schizophrenia, fewer ad- verse effects.
出处
《中国民康医学》
2008年第15期1712-1713,共2页
Medical Journal of Chinese People’s Health
